View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 23, 2021updated 12 Jul 2022 11:21am

PRA Health Sciences introduces Patient-Centric Trial Development Toolkit

US-based contract research company PRA Health Sciences has launched its Patient-Centric Trial Development Toolkit to identify and mitigate risks to rare disease clinical programmes.

US-based contract research company PRA Health Sciences has launched its Patient-Centric Trial Development Toolkit to identify and mitigate risks to rare disease clinical programmes.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The new toolkit is developed by PRA ’s Center for Rare Diseases in partnership with its Rare Disease Advisory Committee (RDAC) and other patient stakeholders.

It supports clinical development sponsors focusing on rare diseases, patient communities and other stakeholders to operationalise the true patient-centricity in clinical development.

This patient-focused toolkit is designed to reduce risks that often occur in rare disease clinical trials and helps to promote trial participation.

It comprises four digital resources, including a patient-centric protocol risk assessment tool, rapid participation burden survey tool, patient involvement value dossier and a guide for rare disease patients and caregivers.

PRA Health Sciences Center for Rare Diseases senior vice-president Scott Schliebner said: “The main purpose of the toolkit is to guide sponsors in taking a more patient-centric approach in developing clinical trials.

“As an example, the toolkit includes a risk assessment tool that clinical development teams can use to identify risk to the efficiency of a clinical programme.

“The risks that are identified are usually real-world burdens for participants, and the tool provides risk mitigation strategies and solutions for sponsors to consider.”

The toolkit also focuses on reducing the burden on patients to participate in clinical research and avoids significant costs related to inefficiency, high trial dropout rates, protocol amendments, and not being able to complete a trial on time.

PRA Health Sciences ’ new Patient-Centric Trial Development Toolkit is available for download for free.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena